Jubilant Pharmova raises $84.6M in debut local bond issue
What's the deal? Jubilant Pharmova has allotted unsecured non-convertible debentures (NCDs) worth US$108.6M — about $84.6 million — through a private placement, the Indian pharmaceutical company said in a regulatory filing on November 5, 2026.
The terms: It issued 80,000 debentures with a face value of US$1.36K each, carrying an 8.50% annual coupon and maturing in three years, on November 5, 2028. The listed, unsecured NCDs trade on BSE, with no charge created over company assets.
Who backed it? Axis BankDealroom has a profile for this one. Try Dealroom →, the sole banker to the deal, invested US$16.3M of the US$108.6M, with the rest split among mutual funds, insurance companies, and other investors, people familiar with the deal said. It was the company's debut bond issue in the local market.
Why now? The raise lands during a period of heavy investment. Jubilant reported FY26 revenue up 14% to US$1.12B and capital expenditure of US$226.5M, with net debt to EBITDA at 1.3x.
What's the endgame? Management has tied future debt reduction to revenue from expanding sterile-injectables capacity, targeting zero net debt by FY30. Alongside the issue, shareholders were asked to approve a US$339.5M borrowing ceiling — a limit, not an immediate commitment.
The signal: The modest, range-bound leverage suggests the bonds finance growth rather than signal distress. The issue also fits a broader rush of Indian corporates tapping local debt markets: in the same week, Persistent SystemsDealroom has a profile for this one. Try Dealroom → raised US$1.03B in NCDs to fund its NagarroDealroom has a profile for this one. Try Dealroom → acquisition.
Read more: businessupturn.com
Image credit: Generated with Gemini
